Ascletis Pharma presented three key studies at the ADA 2026 Scientific Sessions highlighting its innovative oral treatments for obesity, including ASC39, ASC30, and ASC37. ASC39 showed potent, selective weight loss effects in animal models, ASC30 demonstrated significant dose-dependent weight loss with good safety in human trials, and ASC37 exhibited enhanced oral bioavailability and long half-life in primate studies. These advances position Ascletis to initiate global Phase III trials for ASC30 by late 2026, aiming to offer new effective therapies for metabolic diseases.
GNI Group has agreed to acquire 100% of Ayumi Pharmaceutical Holdings from shareholders led by Blackstone for about ¥44.8 billion. This acquisition significantly expands GNI's commercial footprint in Japan, especially in pain management and rheumatol...
Akash Network (AKT) surged over 14% in 24 hours following a broader altcoin recovery driven by Bitcoin's 2.5% gain. AKT bounced from a previous resistance level turned support around $0.526 and rallied toward $0.96, with volume and development activi...
The funding rate for Bitcoin perpetual futures on OKX has plunged to an extreme annualized -453%, forcing short sellers to pay about 1.3% daily just to hold their positions. This unusually high negative rate indicates a heavy concentration of short b...
The Wegovy pill, a GLP-1 weight-loss medication by Novo Nordisk, has surpassed 3 million prescriptions in the US since its launch on January 5, 2026. This equates to one prescription filled every five seconds, marking it as one of the most successful...
Everest Medicines has acquired the rights from Corxel Pharmaceuticals to develop, manufacture, and commercialize VIZZ (LNZ100), an aceclidine-based eye drop for presbyopia, in Greater China. The drug's New Drug Application was submitted in China in S...
